Skip to main content

Table 1 PI3K, AKT, and mTOR inhibitors selected for preclinical and clinical development(main PI3K/AKT/mTOR inhibitors in clinical trials) [73,74,75,76,77,78,79,80,81]

From: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours

InhibitorCompound or drugTargetsTumor types currently under investigation
PI3KLY294002Pan-class I PI3KAdvanced solid tumors
Buparlisib (BKM120)Pan-class I PI3KAdvanced solid tumors
SAR245408 (XL-147)Pan-class I PI3KAdvanced solid tumors
Sonolisib (PX-866)P110-Delta, gammaPhase II and III trials in NHL and CLL are underway, both alone and in combination with hantiCD20 antibodies
Pictilisib (GDC-0941)P110-alpha, DeltaAdded alpha specificity may provide benefit in MCLandsome others versus delta-only inhibitors
Taselisib (GDC-0032)P110-alpha, DeltaAdvanced solid tumors and metastatic breast cancer (ERþ)
AKTPirifosineAKTAdvanced solid tumors, multiple myeloma
Palomid529(P529)AKTAdvanced solid tumors, breast cancer, cervical cancer, endometrial cancer, leukemias, melanoma, multiple myeloma
GSK2141795AKTAdvanced solid tumors, breast cancer, cervical cancer, endometrial cancer, leukemias, melanoma, multiple myeloma
MK-2206AKTAdvanced solid tumors, breast cancer, colorectal cancer, endometrial cancer, head & neck cancer, lung cancer, lymphomas, pancreatic cancer, prostate cancer
mTOREverolimus(RAD001)mTORC1Approved for the treatment of renal cell carcinoma, subependymal giant cell astrocytoma associated with tuberous sclerosis, pancreatic neuroendocrine tumors, and ERþ breast cancer
TemsirolimusmTORC1Approved for the treatment of renal cell carcinoma
RapamycinmTORC1Advanced solid tumors, multiple myeloma
DualNVP-BEZ235 (BEZ-235)P110, mTORC1/2Advanced solid tumors, multiple myeloma
SAR245409(XL765)PI3K/mTORAdvanced solid tumors, CLL, indolent non-Hodgkin lymphoma, mantle cell lymphoma, ovarian cancer
GDC-0980PI3K/mTORSolid cancers, non-Hodgkin lymphoma, breast cancer, prostate cancer